Novel Combination Therapy Explored for Advanced Rectal Cancer in Phase II Study

Locally advanced middle and low rectal cancer is a challenging disease, often requiring neoadjuvant chemoradiotherapy followed by surgery. Patients with pMMR/MSS (proficient mismatch repair/microsatellite stable) tumors often show limited response to immunotherapy alone, presenting a significant hurdle in treatment. Current standard treatments, while effective for some, still leave a substantial portion of patients with residual disease or recurrence, highlighting the urgent need for more effective neoadjuvant strategies to improve patient outcomes.

As an active, not yet recruiting Phase II clinical study, specific results are not yet available. However, the study is designed to evaluate the efficacy and safety of this novel combination therapy. The primary endpoint is expected to be the pathological complete response (pCR) rate, which signifies the complete absence of viable tumor cells in the resected specimen after neoadjuvant treatment. The most critical objective is to determine if this novel combination can achieve a significantly higher pCR rate for pMMR/MSS locally advanced rectal cancer, potentially exceeding historical rates. Secondary endpoints will include disease-free survival (DFS), overall survival (OS), and the incidence of treatment-related adverse events (TRAEs) to provide a comprehensive safety profile. Researchers will also assess the objective response rate (ORR) and R0 resection rate (complete tumor removal with clear margins) to further quantify the treatment's effectiveness.